Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05674513
Other study ID # OHSU IRB 24952
Secondary ID 1R01HD105866-01A
Status Recruiting
Phase Phase 4
First received
Last updated
Start date January 9, 2023
Est. completion date December 31, 2027

Study information

Verified date April 2023
Source Oregon Health and Science University
Contact Women's Health Research Unit Department of OB/GYN
Phone 503-494-3666
Email whru@ohsu.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to learn more about why some people are at greater risk for oral emergency contraceptive failure while others are not. The investigators want to learn if genetic differences impact the risk of emergency contraception failure.


Description:

Each of us can respond differently to a drug or medication based on our genetics. An emergency contraceptive, ulipristal acetate or UPA, normally works by stopping or delaying the ovary from releasing an egg (ovulation). Our bodies break down UPA in order to use it through a system call the cytochrome P450 pathway but this pathway can be faster or slower depending on our genetics. The investigators want to learn more about how our individual genetic differences in this pathway change how the ovary responds to UPA. The overall goal of this research is to improve the effectiveness of emergency contraception for all people.


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date December 31, 2027
Est. primary completion date December 31, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Generally healthy women - Aged 18-40 - regular menses (every 21-35 days) experiencing ovulatory cycles proven by a single progesterone level of 3 ng/mL or greater during the luteal phase of the screening cycle. Exclusion Criteria: - Pregnant, seeking pregnancy, or breastfeeding - Known allergy to study medication - Recent use of hormonal contraception - Irregular periods (<21 days or >35 day cycles) - Routine use of nonsteroidal anti-inflammatory drugs - Metabolic disorders - Smoking - Any condition that would preclude the provision of informed consent - Using drugs (within 2 weeks of study enrollment) known to interfere with the metabolism of UPA as well as drugs known to be CYP3A4 inducers, inhibitors, or CYP3A drug substrates

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ulipristal acetate
Evaluating the pharmacodynamic and pharmacokinetic outcomes after 1 dose of Ulipristal acetate 30mg in individuals with and without active CYP3A5 alleles

Locations

Country Name City State
United States OHSU Portland Oregon

Sponsors (2)

Lead Sponsor Collaborator
Oregon Health and Science University Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Delay in follicular rupture Follicular rupture (yes/no) by ultrasound. Defined as the disappearance of or >50% reduction in size of the leading follicle over 1 menstrual cycle (assessed up to approximately 30 days)
Primary Concentration of UPA mean concentration maximum (Cmax) for UPA 5 days after taking study drug
See also
  Status Clinical Trial Phase
Completed NCT03279120 - Safety, PK, and PD Study of IVRs Releasing TFV and LNG Phase 1
Withdrawn NCT03725358 - A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon. N/A
Completed NCT01170390 - Oral Contraceptives and Body Mass Index Phase 4
Recruiting NCT05932537 - Ablation of Subcutaneous Contraceptive Implants in the Operating Room
Withdrawn NCT04882137 - Barriers to Referring Adolescent Women for Etonogestrel Implant. N/A
Completed NCT02613039 - Oral Contraceptive Therapy and Sexuality Phase 4
Completed NCT01425060 - Improving Effective Contraceptive Use Among Opioid-maintained Women Phase 1
Completed NCT03626597 - Community-based Provision of Urine Pregnancy Tests as Linkage to Reproductive Health Services N/A
Recruiting NCT04558229 - RCT Evaluating Standardized Counseling on Early Discontinuation for Irregular Bleeding in Nexplanon Users Phase 4
Recruiting NCT05644886 - Pilot Study on Engaging Family Physicians in Family Planning in Pakistan N/A
Completed NCT03253783 - The Evaluation of Pulse: A Mobile Health App and Teen Pregnancy Prevention Program N/A
Completed NCT04043130 - The Evaluation of Pulse: A Mobile Health App and Teen Pregnancy Prevention Program N/A
Completed NCT03571932 - Assessment of Family Planning and Immunization Service Integration in Liberia
Completed NCT03336346 - Effect of Dolutegravir on Etonogestrel Levels in HIV-infected Women in Botswana
Active, not recruiting NCT03984695 - Sexual Health Empowerment for Women's Health N/A
Completed NCT02411357 - Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II N/A
Completed NCT05806463 - Efficacy of Mother's Time in Ethiopia N/A
Recruiting NCT05328648 - Randomized Controlled Trial to Address Unintended Pregnancy Rates in Low Resource Settings N/A
Active, not recruiting NCT05061472 - A 6-month Observational Study on Combined Oral Contraceptives and Body Weight in Pre-Menopausal Women With Overweight or Obesity
Not yet recruiting NCT05988983 - The Over The Counter Pill National Study